Observational Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Jul 21, 2024; 30(27): 3314-3325
Published online Jul 21, 2024. doi: 10.3748/wjg.v30.i27.3314
Table 1 Descriptive characteristics of the study population, n (%)
Characteristics
Training cohort
Validation cohort
P value
Patients50062
PHLF142 (28.40)22 (35.50)0.250
Sex0.080
Male413 (89.01)45 (72.58)
Female87 (10.99)17 (27.42)
Age in yr, mean ± SD55.70 ± 10.7053.05 ± 10.620.067
TB in mg/dL, median; IQR12.8; 9.9-17.013.4; 9.2-17.20.740
ALB in g/L, median; IQR43; 40.0-46.041; 38.8-45.00.130
ALT in U/L, median; IQR27; 19.0-38.032; 21.0-39.00.250
PT in s, median; IQR12.4; 11.7-13.212.0; 11.5-13.00.080
INR, median; IQR10.5; 9.9-11.110.2; 9.7-10.90.110
PLT as × 109/L, median; IQR148.5; 111.0-197.0167.5; 139.8-192.00.060
GGT in U/L, median; IQR43.0; 11.0-1019.044.5; 16.0-543.00.190
WBC as × 109, median; IQR5.55; 1.84-14.075.88; 2.01-14.300.250
HB in g/L, median; IQR142; 66-203145; 105-2670.200
AFP0.680
≤ 20239 (47.8)27 (43.5)
> 20261 (52.2)35 (56.5)
LS in kPa, median; IQR10.8; 7.9-14.09.6; 8.0-12.30.150
SPA in cm2, median; IQR38.70; 38.50-41.1039.16; 37.90-44.800.370
Tumor size in cm, median; IQR3.1; 0.5-25.03.8; 0.7-13.00.230
Tumor number, median; IQR1; 1.0-15.01; 1.0-2.00.090
RR0.070
Minor400 (80.0)43 (69.4)
Major100 (20.0)19 (30.6)
BL in mL, median; IQR100; 50-200175; 50-3000.390
Clamping time in min, median; IQR15.0; 0-6913.5; 0-600.150
HBV0.570
Positive468 (93.6)60 (96.7)
Negative32 (6.4)2 (3.3)
HBV-DNA level0.680
≥ 103 IU/mL286 (57.2)32 (51.6)
< 103 IU/mL32 (42.8)30 (48.4)
PHLF0.250
Absent358 (71.6)40 (64.5)
Present142 (28.4)22 (35.5)
PHLF ISGLS grade0.310
0-A464 (92.8)55 (88.7)
B-C36 (7.2)7 (11.3)